<DOC>
	<DOCNO>NCT02865122</DOCNO>
	<brief_summary>The objective clinical study evaluate efficacy safety NTRA-9620 compare placebo pediatric subject ( age 28 week postmenstrual age 52 week old ) SBS follow surgical resection</brief_summary>
	<brief_title>Safety Efficacy Study Infant With SBS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>Inclusion Criteria 1 . Subject must least 28 week postmenstrual age 52 week chronological age enrollment . 2 . Subject weight must least 500 gram ( 17.6 ounce ) time enrollment . 3 . After major surgical resection lead SBS , subject maximally 70 % expect bowel length preserve ostomy place ≤ 70 % small bowel available nutrient absorption . Exclusion Criteria 1 . Subject undergone bowel lengthen procedure . 2 . Subject malabsorption disorder due : congenital etiology ( microvilli inclusion disease , tufting enteropathy ) Untreated Hirchsprung 's disease 3 . Uncontrolled systemic infection , acute gastroenteritis , pneumonia , cardiovascular abnormality include EKG finding opinion investigator make infant unstable significant risk complete first 12 week study . 4 . Subjects hyperinsulinemia . 5 . Subjects unexplained recurrent hypoglycemia blood glucose ≤ 50 mg/dL within 48 hour treatment initiation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>52 Weeks</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>